Want to see FR:ALMDT full AI Analyst Report?

Median Technologies (ALMDT) Price & Analysis

20 Followers

ALMDT Stock Chart & Stats

€4.04

€0.10(2.35%)

At close: Jul 31 4:00 PM EDT

€4.04

€0.10(2.35%)

Day’s Range― - ―

52-Week Range€2.26 - €7.27

Previous CloseN/A

Volume515.80K

Average Volume (3M)465.96K

Market Cap

€220.55M

Enterprise Value€180.92

Total Cash (Recent Filing)€18.41M

Total Debt (Recent Filing)€21.76M

Price to Earnings (P/E)―

Beta0.79

Next Earnings

Oct 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.15

Shares Outstanding49,048,060

10 Day Avg. Volume398,206

30 Day Avg. Volume465,957

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)-4.95

Price to Sales (P/S)7.45

P/FCF Ratio-9.58

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.44

Revenue Forecast (FY)€25.43M

Bulls Say, Bears Say

Bulls Say

Revenue GrowthThe acceleration in reported revenue growth indicates continued demand for Median’s oncology imaging and AI offerings. Sustained expansion would improve operating leverage if delivery costs and pricing discipline improve.

Oncology Imaging SpecializationA focused oncology position gives Median domain expertise across tumor imaging, clinical research and drug development. This specialization can support differentiated workflows and longer-term customer relationships in a technically demanding market.

Dual-market Revenue ModelServing both biopharma trial programs and healthcare providers broadens the commercial opportunity beyond one customer type. Over time, software licensing, services and maintenance could create multiple routes to monetization.

Bears Say

Severe And Persistent LossesPersistent operating and net losses show that revenue growth has not yet produced a viable earnings model. The scale of losses limits internal funding capacity and makes future profitability dependent on major cost or pricing improvements.

Negative Equity And Weak Capital BaseNegative equity materially reduces financial flexibility and leaves the company less able to absorb execution setbacks. A weak capital base can increase dependence on financing and raise dilution or refinancing risks over the medium term.

Ongoing Cash BurnRecurring operating cash outflows indicate that the business is not self-funding despite revenue growth. Continued cash burn may require external capital or balance-sheet support, creating pressure on funding access and shareholder returns.

Median Technologies News

Median Technologies Updates Share Capital and Warrants in Regulatory Filing

Median Technologies ( ($FR:ALMDT) ) has provided an update. Median Technologies has disclosed its latest capital structure and...

12d ago

Median Technologies strikes global Canon partnership to scale AI lung cancer screening

Median Technologies ( ($FR:ALMDT) ) has issued an announcement. Median Technologies has signed a global strategic commercial partnership...

23d ago

Median Technologies strengthens finances as eyonis lung cancer AI wins U.S. and EU approval

Median Technologies ( ($FR:ALMDT) ) has shared an update. Median Technologies, a specialist in AI-based medical imaging software...

1M ago

Stifel Nicolaus Recommends ‘Buy’ for Median Technologies Amid Strategic Financial Moves and Growth Potential

In a report released today, from Stifel Nicolaus reiterated a Buy rating on Median Technologies, with a price...

10M ago

ALMDT FAQ

What was Median Technologies’s price range in the past 12 months?

Median Technologies lowest stock price was €2.26 and its highest was €7.27 in the past 12 months.

What is Median Technologies’s market cap?

Median Technologies’s market cap is €220.55M.

When is Median Technologies’s upcoming earnings report date?

Median Technologies’s upcoming earnings report date is Oct 15, 2026 which is in 54 days.

How were Median Technologies’s earnings last quarter?

Median Technologies released its earnings results on Apr 23, 2026. The company reported -€0.677 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Median Technologies overvalued?

According to Wall Street analysts Median Technologies’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Median Technologies pay dividends?

Median Technologies does not currently pay dividends.

What is Median Technologies’s EPS estimate?

Median Technologies’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Median Technologies have?

Median Technologies has 49,048,060 shares outstanding.

What happened to Median Technologies’s price movement after its last earnings report?

Median Technologies reported an EPS of -€0.677 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.957%.

Which hedge fund is a major shareholder of Median Technologies?

Currently, no hedge funds are holding shares in FR:ALMDT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Median Technologies

Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving markets in France, the United States, Canada, the United Kingdom, China, and beyond. Among its key offerings is iBiops, an innovative, AI-powered software classified as a medical device. This solution comprehensively integrates and optimizes the entire medical imaging workflow. Additionally, Median Technologies provides iSee, a service dedicated to image analysis specifically for clinical trials. Furthermore, the company delivers extensive imaging contract research organization (CRO) services. These encompass a wide range of activities, from study initiation and the management of both image and clinical data, to scientific advisory, independent reviews, image data processing, site support, and final study close-out. Solidifying its commitment to research, Median Technologies maintains a collaborative agreement with the University of California.